Investor Presentation First Nine Months of 2022
138
Investor presentation First nine months of 2022
Novo Nordisk volume market shares in the three insulin
segments
tMU
Long-acting insulin
tMU
Premix insulin
tMU
Fast-acting insulin
NAO
100
80%
80
80%
80
100%
CAGR volume1: 0.2%
MI penetration²: 65.2%
80
60
CAGR volume1: -7.4%
MI penetration²: 47.6%
CAGR volume1: 1.8%
MI penetration²: 83.7%
80%
60%
60
60%
60
60
60
40
40
20
20
40%
40
40
20%
20
40%
40
20%
20
0%
0
Aug
Aug
2022
2017
0
Aug
0%
0
Aug
Aug
2017
2022
2017
Segment volume
-LevemirⓇ
Segment volume
-TresibaⓇ
-Combined
NovoLogⓇ Mix share 70/30
1 CAGR for 5-year period; 2 Includes new-generation insulin. tMU: Thousand mega units
Source: IQVIA monthly MAT, Aug 2022 volume figures
NN: Novo Nordisk
Segment volume
FiaspⓇ
60%
40%
20%
0%
Aug
2022
-NovoRapidⓇ
NN combinedView entire presentation